NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nutex Health Inc. (“Nutex” or the “Company”) (NASDAQ: NUTX) and certain officers.   The class action, filed in the United States District Court for the Southern District of Texas, and docketed under 25-cv- 03999, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nutex securities between August 8, 2024 and August 14, 202 ...

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit due to alleged breaches of fiduciary duties by its board of directors, following significant issues related to revenue recognition and internal controls [1][3]. Group 1: Financial Reporting Issues - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release and the filing of its annual report on Form 10-K due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [2]. - The company identified a material weakness in its internal controls over revenue recognition, necessitating additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2]. - Following this announcement, Maravai's share price dropped by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, amid unusually heavy trading volume [2]. Group 2: Allegations in Class Action Complaint - The class action complaint alleges that Maravai's executives made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects [3]. - Specific allegations include the lack of adequate internal controls over financial reporting, inaccurate revenue recognition during fiscal 2024, and overstated goodwill [3]. - The complaint asserts that the positive statements made by the defendants regarding the company's business were materially misleading and lacked a reasonable basis due to these issues [3].